G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance | Zendy

Soundasse Munir | Zendy; Eloïse Thierry | Zendy; Isabelle Malet | Zendy; Frédéric Subra | Zendy; Vincent Cálvez | Zendy; AnneGeneviève Marcelin | Zendy; Eric Deprez | Zendy; Olivier Delelis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance

Author(s) -

Soundasse Munir,

Eloïse Thierry,

Isabelle Malet,

Frédéric Subra,

Vincent Cálvez,

AnneGeneviève Marcelin,

Eric Deprez,

Olivier Delelis

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku474

Subject(s) - dolutegravir , raltegravir , medicine , virology , drug resistance , integrase inhibitor , pharmacology , genetics , biology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load

Strand transfer inhibitors (raltegravir, elvitegravir and dolutegravir) are now commonly used to inhibit HIV-1 integration. To date, three main pathways conferring raltegravir/elvitegravir resistance, involving residues Y143, Q148 and N155, have been described. However, no pathway has been clearly described for dolutegravir resistance. The aim of this study was to characterize the susceptibility of two mutations, F121Y and G118R, originally described in patients failing raltegravir-containing regimens, to dolutegravir and raltegravir, and then to compare the resistance of these mutations with that of other well-known mutations involved in raltegravir resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research